Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Friday, March 15th.

Cytosorbents Price Performance

CTSO stock opened at $0.88 on Wednesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77. Cytosorbents has a 1 year low of $0.78 and a 1 year high of $4.29. The firm has a market cap of $47.72 million, a P/E ratio of -1.37 and a beta of 0.58. The stock has a 50-day simple moving average of $0.94 and a 200-day simple moving average of $1.17.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. The business had revenue of $8.67 million during the quarter, compared to analyst estimates of $9.29 million. On average, equities analysts predict that Cytosorbents will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds have recently bought and sold shares of the business. Skylands Capital LLC grew its stake in Cytosorbents by 10.5% during the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock valued at $3,612,000 after purchasing an additional 309,543 shares in the last quarter. Avenir Corp grew its stake in Cytosorbents by 12.3% during the 4th quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock valued at $3,387,000 after purchasing an additional 334,005 shares in the last quarter. Neuberger Berman Group LLC grew its stake in Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 299,103 shares in the last quarter. Sargent Investment Group LLC grew its stake in Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after purchasing an additional 51,699 shares in the last quarter. Finally, Raymond James & Associates acquired a new stake in Cytosorbents during the 4th quarter valued at approximately $56,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.